DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20183503

Importance of vaccines in children with Down syndrome

Mohanned Alrahili, Ali Binyamen, Fares Al Otaibi, Abeer Abu Alnour, Majd Alsaadi, Shahad Aloufi, Fatima Al Sadiq, Wejdan Alzahrani, Moath Aljabri, Ahmed Alqarni

Abstract


Down syndrome is the most common chromosomal disorder affecting infants. It is characterized by various morphological features and systemic manifestations. Immune system is one of the main systems affected by trisomy 21, and it dysfunction is the major etiology for the recurrent infections encountered among patients with Down syndrome. Knowledge about immune system defects had made a considerable progress in prevention of infections among those patients, and subsequently decreased the morbidity and mortality among those patients. Many vaccines were recommended to be administered to Down syndrome patients as a means of prophylaxis against potential infections. Therefore, the life expectancy of Down syndrome witnessed a dramatic improvement during the past few decades. The aim of this review article is to discuss the immune system defects in patients with Down syndrome, the types of infections they are prone to, and the vaccines necessary for prophylaxis against these infections.


Keywords


Children, Down syndrome, Immune system, Infection, Vaccines

Full Text:

PDF

References


Buckley S. Precise descriptions of Down syndrome. Down Syndr Res Pract. 2008;12(2):90.

Hodapp RM, DesJardin JL, Ricci LA. Genetic syndromes of mental retardation: should they matter for the early interventionist? Infants Young Child. 2003;16(2):152-60.

Lu J, Shee V. Genetic and epigenetic mechanisms in down syndrome brain. In: Down Syndrome. InTech. 2013.

Stoel-Gammon C. Down syndrome phonology. Developmental patterns and intervention strategies. Down Syndr Res Pract. 2001;7(3):93-100.

Canfield MA, Honein MA, Yuskiv N, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res Part A - Clin Mol Teratol. 2006;76(11):747-56.

National Down Syndrome Society. Down Syndrome Facts. 2015. Available at https://www.ndss.org/about-down-syndrome/down-syndrome-facts/. Accessed 1 June 2018.

Uppal H, Chandran S, Potluri R. Risk factors for mortality in Down syndrome. J Intellect Disabil Res. 2015;59(9):873-81.

De Hingh YCM, Van Der Vossen PW, Gemen EFA. Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr. 2005;147(6):744-7.

Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9-16.

Cocchi G, Mastrocola M, Capelli M, Bastelli A, Vitali F, Corvaglia L. Immunological patterns in young children with Down syndrome: is there a temporal trend? Acta Paediatr. 2007;96(10):1479-82.

Verstegen RHJ, Kusters MAA, Gemen EFA, De Vries E. Down syndrome B-lymphocyte subpopulations, intrinsic defect or decreased T-lymphocyte help. Pediatr Res. 2010;67(5):563-9.

Selikowitz M. Health problems and health checks in school‐aged children with Down syndrome. J Paediatr Child Health. 1992;28(5):383-6.

Mehta PD, Dalton AJ, Mehta SP, Percy ME, Sersen EA, Wisniewski HM. Immunoglobulin G subclasses in older persons with Down syndrome. J Neurol Sci. 1993;117(1-2):186-91.

Lopez V, Ochs HD, Thuline HC, Davis SD, Wedgwood RJ. Defective antibody response to bacteriophage ØX 174 in Down syndrome. J Pediatr. 1975;86(2):207-11.

Hawkes RA, Philbrook SC, Boughton CR. The response of institutionalized Down’s syndrome subjects to enterovirus infections. J Hyg (Lond). 1980;84(3):433-41.

Ferreira CT, Leite JC, Taniguchi A, Vieira SM, Pereira-Lima J, da Silveira TR. Immunogenicity and safety of an inactivated hepatitis A vaccine in children with Down syndrome. J Pediatr Gastroenterol Nutr. 2004;39(4):337-40.

Kim YS, Cho KO, Lee HJ, Kim SY, Sato Y, Cho YJ. Down syndrome candidate region 1 increases the stability of the IκBα protein implications for its anti-inflammatory effects. J Biol Chem. 2006;281(51):39051-61.

Wilcock DM, Griffin WST. Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation. 2013;10(1):864.

Cuadrado E, Barrena MJ. Immune dysfunction in Down’s syndrome: Primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol. 1996;78(3):209-14.

Guazzarotti L, Trabattoni D, Castelletti E. T lymphocyte maturation is impaired in healthy young individuals carrying trisomy 21 (Down syndrome). Am J Intellect Dev Disabil. 2009;114(2):100-9.

Nisihara RM, Utiyama SRR, Oliveira NP, Messias-Reason IJ. Mannan-binding lectin deficiency increases the risk of recurrent infections in children with Down’s syndrome. Hum Immunol. 2010;71(1):63-6.

Austeng ME, Akre H, Øverland B, Abdelnoor M, Falkenberg ES, Kværner KJ. Otitis media with effusion in children with in Down syndrome. Int J Pediatr Otorhinolaryngol. 2013;77(8):1329-32.

Sheikh S, Allen E, Shell R. Chronic aspiration without gastroesophageal reflux as a cause of chronic respiratory symptoms in neurologically normal infants. Chest. 2001;120(4):1190-5.

Zárate N, Mearin F, Hidalgo A, Malagelada JR. Prospective evaluation of esophageal motor dysfunction in Down’s syndrome. Am J Gastroenterol. 2001;96(6):1718-24.

Bloemers BLP, van Furth AM, Weijerman ME. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study. Pediatr. 2007;120(4):e1076-81.

Megged O, Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J. 2010;29(7):672-3.

Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23(9):824-8.

Hilton JM, Fitzgerald DA, Cooper DM. Respiratory morbidity of hospitalized children with Trisomy 21. J Paediatr Child Health. 1999;35(4):383-6.

Espa D. Vaccination schedule for people with Down’s syndrome, 2012. Int Med Rev Down Syndr. 2011;15(3):45-7.

Rauet JC. Diseases susceptible to vaccination and Down syndrome. Medical Rev Int on Down syndrome. 2008;12(2):18-24.

Joshi AY, Abraham RS, Snyder MR, Boyce TG. Immune evaluation and vaccine responses in Down syndrome: Evidence of immunodeficiency? Vaccine. 2011;29(31):5040-6.

Volti LS, Mattina T, Mauro L. Safety and effectiveness of an acellular pertussis vaccine in subjects with Down’s syndrome. Childs Nerv Syst. 1996;12(2):100-2.

Garibotti EJ, Cervellini PM, Piccolo MC. Planktonic microcrustaceans and limnological characteristics of two Pampean lagoons (Buenos Aires, Argentina). Limnetica. 2009;28(1):91-104.

Kusters MA, Jol-Van Der Zijde CM, Van Tol MJ. Impaired avidity maturation after tetanus toxoid booster in children with down syndrome. Pediatr Infect Dis J. 2011;30(4):357-9.